CN100450475C - 用于治疗注意力缺陷多动障碍及多发性硬化症疲劳的含有莫达非尼的组合物 - Google Patents

用于治疗注意力缺陷多动障碍及多发性硬化症疲劳的含有莫达非尼的组合物 Download PDF

Info

Publication number
CN100450475C
CN100450475C CNB008111820A CN00811182A CN100450475C CN 100450475 C CN100450475 C CN 100450475C CN B008111820 A CNB008111820 A CN B008111820A CN 00811182 A CN00811182 A CN 00811182A CN 100450475 C CN100450475 C CN 100450475C
Authority
CN
China
Prior art keywords
modafinil
fatigue
multiple sclerosis
treatment
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008111820A
Other languages
English (en)
Chinese (zh)
Other versions
CN1635875A (zh
Inventor
马修·S·米勒
托马斯·E·斯卡梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN1635875A publication Critical patent/CN1635875A/zh
Application granted granted Critical
Publication of CN100450475C publication Critical patent/CN100450475C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNB008111820A 1999-08-16 2000-08-16 用于治疗注意力缺陷多动障碍及多发性硬化症疲劳的含有莫达非尼的组合物 Expired - Fee Related CN100450475C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14961299P 1999-08-16 1999-08-16
US60/149,612 1999-08-16
US09/638,353 2000-08-15
US09/638,353 US6346548B1 (en) 1999-08-16 2000-08-15 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue

Publications (2)

Publication Number Publication Date
CN1635875A CN1635875A (zh) 2005-07-06
CN100450475C true CN100450475C (zh) 2009-01-14

Family

ID=26846889

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008111820A Expired - Fee Related CN100450475C (zh) 1999-08-16 2000-08-16 用于治疗注意力缺陷多动障碍及多发性硬化症疲劳的含有莫达非尼的组合物

Country Status (19)

Country Link
US (3) US6346548B1 (https=)
EP (1) EP1253918B1 (https=)
JP (1) JP5542291B2 (https=)
KR (1) KR100728080B1 (https=)
CN (1) CN100450475C (https=)
AT (1) ATE410157T1 (https=)
AU (1) AU778360B2 (https=)
BR (1) BR0013555A (https=)
CA (2) CA2689735A1 (https=)
CY (1) CY1109079T1 (https=)
DE (1) DE60040487D1 (https=)
DK (1) DK1253918T3 (https=)
ES (1) ES2313902T3 (https=)
IL (2) IL147794A0 (https=)
MX (1) MXPA02001587A (https=)
NO (1) NO331307B1 (https=)
NZ (1) NZ516767A (https=)
PT (1) PT1253918E (https=)
WO (1) WO2001012170A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
ES2277937T3 (es) * 2000-07-27 2007-08-01 Teva Pharmaceutical Industries Ltd. Modafinilo puro y cristalino y su procedimiento de preparacion.
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
JP2004536819A (ja) 2001-06-11 2004-12-09 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US6821979B2 (en) * 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
CN101606916B (zh) * 2002-09-13 2011-02-09 赛福伦公司 莫达非尼片剂及其应用
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
AR045423A1 (es) * 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
US7449481B2 (en) * 2004-04-13 2008-11-11 Cephalon, Inc. Thio-substituted biaryl-methanesulfinyl derivatives
US7314875B2 (en) * 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives
EP1586560A1 (en) * 2004-04-13 2005-10-19 Cephalon, Inc. Thio-substituted arylmethanesulfinyl derivatives
US7297817B2 (en) * 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
CA2575790A1 (en) * 2004-09-24 2006-03-30 Centre For Addiction And Mental Health The use of a modafinil compound for the treatment of problem gambling
JP2009503020A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090023712A1 (en) * 2006-02-18 2009-01-22 Boehringer Ingelheim International Gmbh Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
MX2008013827A (es) * 2006-05-09 2008-11-10 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
EP2037927B1 (en) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) * 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
US20100010092A1 (en) * 2006-12-19 2010-01-14 Arless Ltd. Use of modafinil to treat restless leg syndrome
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
US9289403B2 (en) * 2007-03-09 2016-03-22 The Board of Trustees of the University of Arizona Use of modafinil to treat spasticity
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
FR2970711B1 (fr) 2011-01-20 2016-03-04 Hopitaux Paris Assist Publique La lauflumide et ses enantiomeres, preparation et utilisations therapeutiques
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
KR102150417B1 (ko) * 2018-08-29 2020-09-01 경북대학교 산학협력단 복외측전시각영역 내 성상세포의 광유전학적 자극을 통한 수면 유도 동물 모델 및 이를 이용한 수면 제어제의 스크리닝 방법
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177290A (en) * 1977-03-31 1979-12-04 Laboratoire L. Lafon Acetamide derivatives
US5180745A (en) * 1990-06-14 1993-01-19 Laboratoire L. Lafon Method for providing a neuroprotective effect
US5401776A (en) * 1992-10-23 1995-03-28 Laboratoire L. Lafon Use of modafinil for the treatment of urinary and fecal incontinence

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2707637B1 (fr) 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
ATE294577T1 (de) * 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177290A (en) * 1977-03-31 1979-12-04 Laboratoire L. Lafon Acetamide derivatives
US5180745A (en) * 1990-06-14 1993-01-19 Laboratoire L. Lafon Method for providing a neuroprotective effect
US5401776A (en) * 1992-10-23 1995-03-28 Laboratoire L. Lafon Use of modafinil for the treatment of urinary and fecal incontinence

Also Published As

Publication number Publication date
US6488164B2 (en) 2002-12-03
US6346548B1 (en) 2002-02-12
US20030069313A1 (en) 2003-04-10
JP5542291B2 (ja) 2014-07-09
HK1051006A1 (en) 2003-07-18
CY1109079T1 (el) 2014-07-02
ES2313902T3 (es) 2009-03-16
CN1635875A (zh) 2005-07-06
KR100728080B1 (ko) 2007-06-14
EP1253918B1 (en) 2008-10-08
KR20020038726A (ko) 2002-05-23
BR0013555A (pt) 2007-03-27
WO2001012170A2 (en) 2001-02-22
ATE410157T1 (de) 2008-10-15
NZ516767A (en) 2004-03-26
NO331307B1 (no) 2011-11-21
AU778360B2 (en) 2004-12-02
CA2380673C (en) 2010-03-30
NO20020772D0 (no) 2002-02-15
EP1253918A2 (en) 2002-11-06
DE60040487D1 (de) 2008-11-20
CA2380673A1 (en) 2001-02-22
US20020082301A1 (en) 2002-06-27
DK1253918T3 (da) 2008-12-08
US7087647B2 (en) 2006-08-08
NO20020772L (no) 2002-02-15
IL147794A0 (en) 2002-08-14
PT1253918E (pt) 2008-11-20
AU6642400A (en) 2001-03-13
JP2003527320A (ja) 2003-09-16
MXPA02001587A (es) 2003-07-21
IL147794A (en) 2007-07-04
WO2001012170A3 (en) 2002-09-06
CA2689735A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
CN100450475C (zh) 用于治疗注意力缺陷多动障碍及多发性硬化症疲劳的含有莫达非尼的组合物
Walker et al. Schizophrenia: a neural diathesis-stress model.
US20110053859A1 (en) Methods to reduce the effects of sleep deprivation
Roche et al. Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat
CA2740029C (en) Pharmaceutical composition for treatment of fibromyalgia
TWI291872B (en) Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US20040092589A1 (en) Use of retinoic acid for treatment of autism
Simeon et al. Computerized electroencephalogram: a model of understanding the brain function in childhood psychosis and its treatment
Frederiksen et al. ACTH 4–9 analogue (Org 2766) in depressed elderly patients: I. Effect on depressed mood
HK1051006B (en) Compositions comprising modafinil for the treatment attention deficit hyperactivity disorder
Oslin et al. Neurotransmitter-Based Therapeutic Strategies in Late-Life Alcoholism
TW202339779A (zh) 痘苗病毒致炎兔皮提取物治療帕金森病的用途
JPH08500577A (ja) パニック障害の治療に関連するｃｃｋペプチドの血中濃度
Hardan Neurobiology of Autism and Other Pervasive Developmental Disorders: Basic Mechanisms and Therapeutic Interventions
Van Matre Neurobiological basis of self-injurious behavior: Following convergent pathways toward novel pharmacotherapy
Katz et al. Desmopressin (DDAVP) treatment in adult sleep‐related enuresis
Class et al. Patent application title: METHODS TO REDUCE THE EFFECTS OF SLEEP DEPRIVATION Inventors: Samuel A. Deadwyler (Lewisville, NC, US) Robert E. Hampson (Kernersville, NC, US) Linda Porrino (Lewisville, NC, US) Michael Todd (Winston Salem, NC, US) Thomas N. Thannickal (Winnetka, CA, US) Yuan-Yan Lai (North Hills, CA, US) Jerome M. Siegel (Northridge, CA, US) Assignees: The US Government Respresented by the Department of Veterans Affairs
Block et al. Nunzio Pomara, MD, ¹² Dennis Deptula, Ph. D., ¹² Marietta Medel, MD,'Robert I.
Recurring et al. 531 Teratogenicity of Psychotherapeutic
HK40016106A (en) Methods of treating seizure disorders and prader-willi syndrome
HK1155659B (en) Pharmaceutical composition for treatment of fibromyalgia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090114

Termination date: 20170816

CF01 Termination of patent right due to non-payment of annual fee